$CRDF
Cardiff Oncology, Inc. Stock $crdf

$crdf Overview Financials Valuation SEC Filings Company Website

2016 Q3 Form 10-Q Financial Statement

#000162828016021098 Filed on November 09, 2016

Income Statement

Concept	2016 Q3	2015 Q3
Revenue	$89.00K	$58.00K
YoY Change	53.45%	1.75%
Cost Of Revenue	$424.6K	$173.5K
YoY Change	144.65%
Gross Profit	-$335.6K	-$115.5K
YoY Change	190.43%	-302.7%
Gross Profit Margin	-377.03%	-199.2%
Selling, General & Admin	$5.652M	$3.747M
YoY Change	50.84%	86.67%
% of Gross Profit
Research & Development	$3.937M	$2.547M
YoY Change	54.62%	27.95%
% of Gross Profit
Depreciation & Amortization	$200.0K	$100.0K
YoY Change	100.0%	66.67%
% of Gross Profit
Operating Expenses	$10.01M	$6.467M
YoY Change	54.83%	61.8%
Operating Profit	-$9.924M	-$6.410M
YoY Change	54.84%	62.67%
Interest Expense	-$270.0K	$352.7K
YoY Change	-176.55%	-9.53%
% of Operating Profit
Other Income/Expense, Net	$0.00	-$8.130K
YoY Change	-100.0%	-57.78%
Pretax Income	-$10.19M	-$2.740M
YoY Change	271.9%	-49.07%
Income Tax
% Of Pretax Income
Net Earnings	-$10.19M	-$2.736M
YoY Change	272.51%	-49.1%
Net Earnings / Revenue	-11450.87%	-4716.95%
Basic Earnings Per Share	-$0.34	-$0.10
Diluted Earnings Per Share	-$0.34	-$0.23
COMMON SHARES
Basic Shares Outstanding	30.34M shares	28.56M shares
Diluted Shares Outstanding	30.34M shares	29.13M shares

Balance Sheet

Concept	2016 Q3	2015 Q3
SHORT-TERM ASSETS
Cash & Short-Term Investments	$46.90M	$74.10M
YoY Change	-36.71%	137.5%
Cash & Equivalents	$22.57M	$74.15M
Short-Term Investments	$24.40M
Other Short-Term Assets	$900.0K	$600.0K
YoY Change	50.0%	100.0%
Inventory
Prepaid Expenses
Receivables	$85.15K	$66.97K
Other Receivables	$0.00	$0.00
Total Short-Term Assets	$47.98M	$74.82M
YoY Change	-35.87%	136.76%
LONG-TERM ASSETS
Property, Plant & Equipment	$4.655M	$1.842M
YoY Change	152.68%	130.28%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets	$371.2K	$362.9K
YoY Change	2.29%	20.98%
Total Long-Term Assets	$5.026M	$2.205M
YoY Change	127.93%	83.76%
TOTAL ASSETS
Total Short-Term Assets	$47.98M	$74.82M
Total Long-Term Assets	$5.026M	$2.205M
Total Assets	$53.00M	$77.02M
YoY Change	-31.18%	134.83%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$925.2K	$1.100M
YoY Change	-15.9%	120.01%
Accrued Expenses	$4.559M	$2.124M
YoY Change	114.63%	11.79%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00
YoY Change
Long-Term Debt Due	$800.0K	$3.700M
YoY Change	-78.38%	362.5%
Total Short-Term Liabilities	$6.565M	$6.969M
YoY Change	-5.81%	124.82%
LONG-TERM LIABILITIES
Long-Term Debt	$15.60M	$11.50M
YoY Change	35.65%	-17.86%
Other Long-Term Liabilities	$4.100M	$3.700M
YoY Change	10.81%	12.12%
Total Long-Term Liabilities	$19.70M	$15.20M
YoY Change	29.61%	-12.14%
TOTAL LIABILITIES
Total Short-Term Liabilities	$6.565M	$6.969M
Total Long-Term Liabilities	$19.70M	$15.20M
Total Liabilities	$26.23M	$22.16M
YoY Change	18.34%	8.65%
SHAREHOLDERS EQUITY
Retained Earnings	-$139.6M	-$101.5M
YoY Change	37.5%
Common Stock	$3.060K	$2.972K
YoY Change	2.96%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$26.77M	$54.86M
YoY Change
Total Liabilities & Shareholders Equity	$53.00M	$77.02M
YoY Change	-31.18%	134.83%

Cashflow Statement

Concept	2016 Q3	2015 Q3
OPERATING ACTIVITIES
Net Income	-$10.19M	-$2.736M
YoY Change	272.51%	-49.1%
Depreciation, Depletion And Amortization	$200.0K	$100.0K
YoY Change	100.0%	66.67%
Cash From Operating Activities	-$7.050M	-$5.130M
YoY Change	37.43%	50.44%
INVESTING ACTIVITIES
Capital Expenditures	-$130.0K	-$570.0K
YoY Change	-77.19%	418.18%
Acquisitions
YoY Change
Other Investing Activities	$3.500M
YoY Change
Cash From Investing Activities	$3.370M	-$570.0K
YoY Change	-691.23%	418.18%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	3.660M	38.55M
YoY Change	-90.51%
NET CHANGE
Cash From Operating Activities	-7.050M	-5.130M
Cash From Investing Activities	3.370M	-570.0K
Cash From Financing Activities	3.660M	38.55M
Net Change In Cash	-20.00K	32.85M
YoY Change	-100.06%	-1033.24%
FREE CASH FLOW
Cash From Operating Activities	-$7.050M	-$5.130M
Capital Expenditures	-$130.0K	-$570.0K
Free Cash Flow	-$6.920M	-$4.560M
YoY Change	51.75%	38.18%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
	dei	Amendment Flag AmendmentFlag	false
	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	Q3
	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2016
	dei	Document Period End Date DocumentPeriodEndDate	2016-09-30
	dei	Document Type DocumentType	10-Q
	dei	Entity Central Index Key EntityCentralIndexKey	0001213037
CY2016Q4	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	30615406	shares
	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
	trov	Class Of Warrant Or Right Weighted Average Exercise Price Of Warrants Or Rights Expired ClassOfWarrantOrRightWeightedAverageExercisePriceOfWarrantsOrRightsExpired	8.00
	trov	Class Of Warrant Or Right Term Of Outstanding Warrants Or Rights ClassOfWarrantOrRightTermOfOutstandingWarrantsOrRights	P1Y10M6D
CY2015Q4	trov	Class Of Warrant Or Right Weighted Average Exercise Price Of Warrants Or Rights ClassOfWarrantOrRightWeightedAverageExercisePriceOfWarrantsOrRights	3.86
CY2016Q3	trov	Class Of Warrant Or Right Weighted Average Exercise Price Of Warrants Or Rights ClassOfWarrantOrRightWeightedAverageExercisePriceOfWarrantsOrRights	3.82
	dei	Entity Filer Category EntityFilerCategory	Accelerated Filer
	dei	Entity Registrant Name EntityRegistrantName	Trovagene, Inc.
CY2015Q3	trov	Adjustment For Change In Unrealized Gain Loss On Derivatives AdjustmentForChangeInUnrealizedGainLossOnDerivatives	-4017212	USD
	trov	Adjustment For Change In Unrealized Gain Loss On Derivatives AdjustmentForChangeInUnrealizedGainLossOnDerivatives	-4017212	USD
CY2016Q3	trov	Adjustment For Change In Unrealized Gain Loss On Derivatives AdjustmentForChangeInUnrealizedGainLossOnDerivatives	0	USD
	trov	Adjustment For Change In Unrealized Gain Loss On Derivatives AdjustmentForChangeInUnrealizedGainLossOnDerivatives	-533750	USD
	trov	Adjustments To Additional Paid In Capital Warrants Reclassified Amount AdjustmentsToAdditionalPaidInCapitalWarrantsReclassifiedAmount	-435365	USD
	trov	Adjustments To Additional Paid In Capital Warrants Reclassified Amount AdjustmentsToAdditionalPaidInCapitalWarrantsReclassifiedAmount	0	USD
CY2016Q2	trov	Area Of Land After Expansion AreaOfLandAfterExpansion	26100	sqft
	trov	Class Of Warrant Or Right Number Expired ClassOfWarrantOrRightNumberExpired	50000	shares
	trov	Class Of Warrant Or Right Number Granted ClassOfWarrantOrRightNumberGranted	30992	shares
CY2014	trov	Class Of Warrant Or Right Term Of Outstanding Warrants Or Rights ClassOfWarrantOrRightTermOfOutstandingWarrantsOrRights	P2Y6M
	trov	Class Of Warrant Or Right Weighted Average Exercise Price Of Warrants Or Rights Granted ClassOfWarrantOrRightWeightedAverageExercisePriceOfWarrantsOrRightsGranted	4.84
CY2015Q3	trov	Comprehensive Income Loss Availableto Common Stockholders Basic ComprehensiveIncomeLossAvailabletoCommonStockholdersBasic	-2741889	USD
	trov	Comprehensive Income Loss Availableto Common Stockholders Basic ComprehensiveIncomeLossAvailabletoCommonStockholdersBasic	-20108424	USD
CY2016Q3	trov	Comprehensive Income Loss Availableto Common Stockholders Basic ComprehensiveIncomeLossAvailabletoCommonStockholdersBasic	-10205410	USD
	trov	Comprehensive Income Loss Availableto Common Stockholders Basic ComprehensiveIncomeLossAvailabletoCommonStockholdersBasic	-30678990	USD
CY2015Q3	trov	Diagnostic Service Revenue DiagnosticServiceRevenue	6026	USD
	trov	Diagnostic Service Revenue DiagnosticServiceRevenue	10712	USD
CY2016Q3	trov	Diagnostic Service Revenue DiagnosticServiceRevenue	37978	USD
	trov	Diagnostic Service Revenue DiagnosticServiceRevenue	69558	USD
	trov	Leaseholdimprovementspaidforbylessor Leaseholdimprovementspaidforbylessor	0	USD
	trov	Leaseholdimprovementspaidforbylessor Leaseholdimprovementspaidforbylessor	1860000	USD
CY2015Q4	trov	Operating Lease Monthly Rent OperatingLeaseMonthlyRent	3100	USD
CY2016Q2	trov	Operating Lease Monthly Rent OperatingLeaseMonthlyRent	68000	USD
	trov	Operating Lease Monthly Rent OperatingLeaseMonthlyRent	60000	USD
CY2015Q3	trov	Original Value Of Warrants OriginalValueOfWarrants	0	USD
CY2016Q3	trov	Original Value Of Warrants OriginalValueOfWarrants	148885	USD
	trov	Preferred Stock Dividend Accrued PreferredStockDividendAccrued	18180	USD
	trov	Preferred Stock Dividend Accrued PreferredStockDividendAccrued	18180	USD
	trov	Share Based Compensation Number Of Options Issued Over Stock Option Authorized ShareBasedCompensationNumberOfOptionsIssuedOverStockOptionAuthorized	996000	shares
CY2015Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	1040868	USD
CY2016Q3	us-gaap	Accounts Payable Current AccountsPayableCurrent	925173	USD
CY2015Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	98736	USD
CY2016Q3	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	85152	USD
	us-gaap	Accretion Amortization Of Discounts And Premiums Investments AccretionAmortizationOfDiscountsAndPremiumsInvestments	0	USD
	us-gaap	Accretion Amortization Of Discounts And Premiums Investments AccretionAmortizationOfDiscountsAndPremiumsInvestments	-61719	USD
	us-gaap	Accretion Of Discount AccretionOfDiscount	59665	USD
	us-gaap	Accretion Of Discount AccretionOfDiscount	105710	USD
CY2015Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	1903797	USD
CY2016Q3	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	4558809	USD
CY2015Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	854782	USD
CY2016Q3	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	1539403	USD
CY2015Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	0	USD
CY2016Q3	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-4742	USD
CY2015Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	157585498	USD
CY2016Q3	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	166337512	USD
CY2015Q3	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	923659	USD
	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	2758846	USD
CY2016Q3	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	1829371	USD
	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	5942392	USD
	us-gaap	Amortization Of Debt Discount Premium AmortizationOfDebtDiscountPremium	253028	USD
	us-gaap	Amortization Of Debt Discount Premium AmortizationOfDebtDiscountPremium	266423	USD
	us-gaap	Amortization Of Deferred Leasing Fees AmortizationOfDeferredLeasingFees	0	USD
	us-gaap	Amortization Of Deferred Leasing Fees AmortizationOfDeferredLeasingFees	-133378	USD
	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	11143202	shares
	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	11053250	shares
CY2016Q3	us-gaap	Area Of Land AreaOfLand	22600	sqft
CY2015Q4	us-gaap	Area Of Land AreaOfLand	2300	sqft
CY2015Q4	us-gaap	Assets Assets	71445651	USD
CY2016Q3	us-gaap	Assets Assets	53003670	USD
CY2015Q4	us-gaap	Assets Current AssetsCurrent	68381068	USD
CY2016Q3	us-gaap	Assets Current AssetsCurrent	47977551	USD
CY2016Q3	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax	2162	USD
CY2016Q3	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax	5027	USD
CY2016Q3	us-gaap	Available For Sale Debt Securities Amortized Cost Basis AvailableForSaleDebtSecuritiesAmortizedCostBasis	15890304	USD
CY2016Q3	us-gaap	Available For Sale Securities AvailableForSaleSecurities	24376904	USD
CY2016Q3	us-gaap	Available For Sale Securities Debt Securities AvailableForSaleSecuritiesDebtSecurities	15887439	USD
CY2016Q3	us-gaap	Available For Sale Securities Short Term Investments Amortized Cost AvailableForSaleSecuritiesShortTermInvestmentsAmortizedCost	24379769	USD
CY2014Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	27293798	USD
CY2015Q3	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	74149797	USD
CY2015Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	67493047	USD
CY2016Q3	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	22569107	USD
CY2015Q4	us-gaap	Class Of Warrant Or Right Outstanding ClassOfWarrantOrRightOutstanding	5533242	shares
CY2016Q3	us-gaap	Class Of Warrant Or Right Outstanding ClassOfWarrantOrRightOutstanding	5514234	shares
CY2016Q3	us-gaap	Commercial Paper CommercialPaper	8489465	USD
CY2015Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		USD
CY2016Q3	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		USD
CY2015Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2016Q3	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2015Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	150000000	shares
CY2016Q3	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	150000000	shares
CY2015Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	29737601	shares
CY2016Q3	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	30599140	shares
CY2015Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	29737601	shares
CY2016Q3	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	30599140	shares
CY2015Q4	us-gaap	Common Stock Value CommonStockValue	2974	USD
CY2016Q3	us-gaap	Common Stock Value CommonStockValue	3060	USD
	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	250600	USD
	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	693485	USD
CY2015Q3	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-2735829	USD
	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-20090244	USD
CY2016Q3	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-10199350	USD
	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-30660810	USD
CY2015Q3	us-gaap	Cost Of Revenue CostOfRevenue	173537	USD
	us-gaap	Cost Of Revenue CostOfRevenue	429992	USD
CY2016Q3	us-gaap	Cost Of Revenue CostOfRevenue	424559	USD
	us-gaap	Cost Of Revenue CostOfRevenue	1143293	USD
CY2016Q2	us-gaap	Deferred Rent Credit DeferredRentCredit	1860000	USD
CY2015Q4	us-gaap	Deferred Rent Credit Current DeferredRentCreditCurrent	30614	USD
CY2016Q3	us-gaap	Deferred Rent Credit Current DeferredRentCreditCurrent	279710	USD
CY2015Q4	us-gaap	Deferred Rent Credit Noncurrent DeferredRentCreditNoncurrent	0	USD
CY2016Q3	us-gaap	Deferred Rent Credit Noncurrent DeferredRentCreditNoncurrent	1446912	USD
CY2015Q4	us-gaap	Derivative Liabilities Noncurrent DerivativeLiabilitiesNoncurrent	3297077	USD
CY2016Q3	us-gaap	Derivative Liabilities Noncurrent DerivativeLiabilitiesNoncurrent	2622243	USD
CY2015Q3	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.10
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.80
CY2016Q3	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.34
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-1.02
CY2015Q3	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.23
	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.96
CY2016Q3	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.34
	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-1.04
	us-gaap	Effect Of Exchange Rate On Cash And Cash Equivalents EffectOfExchangeRateOnCashAndCashEquivalents	0	USD
	us-gaap	Effect Of Exchange Rate On Cash And Cash Equivalents EffectOfExchangeRateOnCashAndCashEquivalents	-1544	USD
	us-gaap	Gain Loss On Sale Of Property Plant Equipment GainLossOnSaleOfPropertyPlantEquipment	-4562	USD
	us-gaap	Gain Loss On Sale Of Property Plant Equipment GainLossOnSaleOfPropertyPlantEquipment	0	USD
CY2015Q3	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	1948546	USD
	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	5756047	USD
CY2016Q3	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	2710782	USD
	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	9183761	USD
	us-gaap	Income Taxes Paid IncomeTaxesPaid	800	USD
	us-gaap	Income Taxes Paid IncomeTaxesPaid	4560	USD
	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	616366	USD
	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	2490137	USD
	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	231672	USD
	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	-13584	USD
	us-gaap	Increase Decrease In Accrued Investment Income Receivable IncreaseDecreaseInAccruedInvestmentIncomeReceivable	0	USD
	us-gaap	Increase Decrease In Accrued Investment Income Receivable IncreaseDecreaseInAccruedInvestmentIncomeReceivable	-10122	USD
	us-gaap	Increase Decrease In Other Operating Assets IncreaseDecreaseInOtherOperatingAssets	10273	USD
	us-gaap	Increase Decrease In Other Operating Assets IncreaseDecreaseInOtherOperatingAssets	-2761	USD
	us-gaap	Increase Decrease In Prepaid Expense IncreaseDecreaseInPrepaidExpense	26238	USD
	us-gaap	Increase Decrease In Prepaid Expense IncreaseDecreaseInPrepaidExpense	157051	USD
CY2015Q3	us-gaap	Incremental Common Shares Attributable To Call Options And Warrants IncrementalCommonSharesAttributableToCallOptionsAndWarrants	568024	shares
	us-gaap	Incremental Common Shares Attributable To Call Options And Warrants IncrementalCommonSharesAttributableToCallOptionsAndWarrants	189341	shares
CY2016Q3	us-gaap	Liabilities Current LiabilitiesCurrent	6564716	USD
CY2016Q3	us-gaap	Incremental Common Shares Attributable To Call Options And Warrants IncrementalCommonSharesAttributableToCallOptionsAndWarrants	0	shares
	us-gaap	Incremental Common Shares Attributable To Call Options And Warrants IncrementalCommonSharesAttributableToCallOptionsAndWarrants	117731	shares
CY2015Q3	us-gaap	Interest Income Expense Net InterestIncomeExpenseNet	-335359	USD
	us-gaap	Interest Income Expense Net InterestIncomeExpenseNet	-1100080	USD
CY2016Q3	us-gaap	Interest Income Expense Net InterestIncomeExpenseNet	-354993	USD
	us-gaap	Interest Income Expense Net InterestIncomeExpenseNet	-967522	USD
	us-gaap	Interest Paid InterestPaid	795375	USD
	us-gaap	Interest Paid InterestPaid	806228	USD
CY2015Q4	us-gaap	Lessee Leasing Arrangements Operating Leases Term Of Contract LesseeLeasingArrangementsOperatingLeasesTermOfContract	P3Y
CY2015Q4	us-gaap	Liabilities Liabilities	22744362	USD
CY2016Q3	us-gaap	Liabilities Liabilities	26229271	USD
CY2015Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	71445651	USD
CY2016Q3	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	53003670	USD
CY2015Q4	us-gaap	Liabilities Current LiabilitiesCurrent	8201097	USD
CY2016Q3	us-gaap	Line Of Credit LineOfCredit	1878312	USD
CY2016Q3	us-gaap	Lines Of Credit Current LinesOfCreditCurrent	573929	USD
CY2015Q4	us-gaap	Long Term Debt And Capital Lease Obligations LongTermDebtAndCapitalLeaseObligations	11246188	USD
CY2016Q3	us-gaap	Long Term Debt And Capital Lease Obligations LongTermDebtAndCapitalLeaseObligations	15595400	USD
CY2015Q4	us-gaap	Long Term Debt And Capital Lease Obligations Current LongTermDebtAndCapitalLeaseObligationsCurrent	5225818	USD
CY2016Q3	us-gaap	Long Term Debt And Capital Lease Obligations Current LongTermDebtAndCapitalLeaseObligationsCurrent	801024	USD
CY2016Q3	us-gaap	Long Term Line Of Credit LongTermLineOfCredit	1328355	USD
	us-gaap	Net Cash Provided By Used In Continuing Operations NetCashProvidedByUsedInContinuingOperations	46855999	USD
	us-gaap	Net Cash Provided By Used In Continuing Operations NetCashProvidedByUsedInContinuingOperations	-44923940	USD
	us-gaap	Net Cash Provided By Used In Financing Activities Continuing Operations NetCashProvidedByUsedInFinancingActivitiesContinuingOperations	63423076	USD
	us-gaap	Net Cash Provided By Used In Financing Activities Continuing Operations NetCashProvidedByUsedInFinancingActivitiesContinuingOperations	2361994	USD
	us-gaap	Net Cash Provided By Used In Investing Activities Continuing Operations NetCashProvidedByUsedInInvestingActivitiesContinuingOperations	-1256988	USD
	us-gaap	Net Cash Provided By Used In Investing Activities Continuing Operations NetCashProvidedByUsedInInvestingActivitiesContinuingOperations	-25249392	USD
	us-gaap	Net Cash Provided By Used In Operating Activities Continuing Operations NetCashProvidedByUsedInOperatingActivitiesContinuingOperations	-15310089	USD
	us-gaap	Net Cash Provided By Used In Operating Activities Continuing Operations NetCashProvidedByUsedInOperatingActivitiesContinuingOperations	-22034998	USD
CY2015Q3	us-gaap	Net Income Loss NetIncomeLoss	-2735829	USD
	us-gaap	Net Income Loss NetIncomeLoss	-20090244	USD
CY2016Q3	us-gaap	Net Income Loss NetIncomeLoss	-10191272	USD
	us-gaap	Net Income Loss NetIncomeLoss	-30656068	USD
CY2015Q3	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-2741889	USD
	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-20108424	USD
CY2016Q3	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-10197332	USD
	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-30674248	USD
CY2015Q3	us-gaap	Net Income Loss Available To Common Stockholders Diluted NetIncomeLossAvailableToCommonStockholdersDiluted	-6759101	USD
	us-gaap	Net Income Loss Available To Common Stockholders Diluted NetIncomeLossAvailableToCommonStockholdersDiluted	-24125636	USD
CY2016Q3	us-gaap	Net Income Loss Available To Common Stockholders Diluted NetIncomeLossAvailableToCommonStockholdersDiluted	-10197332	USD
	us-gaap	Net Income Loss Available To Common Stockholders Diluted NetIncomeLossAvailableToCommonStockholdersDiluted	-31207998	USD
CY2015Q3	us-gaap	Operating Expenses OperatingExpenses	6466879	USD
	us-gaap	Operating Expenses OperatingExpenses	18123154	USD
CY2016Q3	us-gaap	Operating Expenses OperatingExpenses	10013601	USD
	us-gaap	Operating Expenses OperatingExpenses	30676380	USD
CY2015Q3	us-gaap	Operating Income Loss OperatingIncomeLoss	-6409552	USD
	us-gaap	Operating Income Loss OperatingIncomeLoss	-17889511	USD
CY2016Q3	us-gaap	Operating Income Loss OperatingIncomeLoss	-9924487	USD
	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	-2865	USD
	us-gaap	Operating Income Loss OperatingIncomeLoss	-30363380	USD
CY2015Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	374004	USD
CY2016Q3	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	371243	USD
CY2015Q3	us-gaap	Other Comprehensive Income Foreign Currency Transaction And Translation Gain Loss Arising During Period Net Of Tax OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax	0	USD
	us-gaap	Other Comprehensive Income Foreign Currency Transaction And Translation Gain Loss Arising During Period Net Of Tax OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax	0	USD
CY2016Q3	us-gaap	Other Comprehensive Income Foreign Currency Transaction And Translation Gain Loss Arising During Period Net Of Tax OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax	-81	USD
	us-gaap	Other Comprehensive Income Foreign Currency Transaction And Translation Gain Loss Arising During Period Net Of Tax OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax	-1877	USD
CY2015Q3	us-gaap	Other Comprehensive Income Loss Net Of Tax OtherComprehensiveIncomeLossNetOfTax	0	USD
	us-gaap	Other Comprehensive Income Loss Net Of Tax OtherComprehensiveIncomeLossNetOfTax	0	USD
CY2016Q3	us-gaap	Other Comprehensive Income Loss Net Of Tax OtherComprehensiveIncomeLossNetOfTax	-8078	USD
	us-gaap	Other Comprehensive Income Loss Net Of Tax OtherComprehensiveIncomeLossNetOfTax	-4742	USD
CY2015Q3	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	0	USD
	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	0	USD
CY2016Q3	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	-7997	USD
CY2015Q3	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-8130	USD
	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	4617	USD
CY2016Q3	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	0	USD
	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	0	USD
CY2015Q3	us-gaap	Other Sales Revenue Net OtherSalesRevenueNet	0	USD
	us-gaap	Other Sales Revenue Net OtherSalesRevenueNet	0	USD
CY2016Q3	us-gaap	Other Sales Revenue Net OtherSalesRevenueNet	3900	USD
	us-gaap	Other Sales Revenue Net OtherSalesRevenueNet	35573	USD
	us-gaap	Payments For Fees PaymentsForFees	0	USD
	us-gaap	Payments For Proceeds From Short Term Investments PaymentsForProceedsFromShortTermInvestments	0	USD
	us-gaap	Payments For Proceeds From Short Term Investments PaymentsForProceedsFromShortTermInvestments	24451611	USD
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	1256988	USD
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	797781	USD
CY2015Q3	us-gaap	Preferred Stock Dividends Income Statement Impact PreferredStockDividendsIncomeStatementImpact	6060	USD
	us-gaap	Preferred Stock Dividends Income Statement Impact PreferredStockDividendsIncomeStatementImpact	18180	USD
CY2016Q3	us-gaap	Preferred Stock Dividends Income Statement Impact PreferredStockDividendsIncomeStatementImpact	6060	USD
	us-gaap	Preferred Stock Dividends Income Statement Impact PreferredStockDividendsIncomeStatementImpact	18180	USD
CY2015Q4	us-gaap	Preferred Stock Liquidation Preference Value PreferredStockLiquidationPreferenceValue	606000	USD
CY2016Q3	us-gaap	Preferred Stock Liquidation Preference Value PreferredStockLiquidationPreferenceValue	606000	USD
CY2015Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.001
CY2016Q3	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.001
CY2015Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	20000000	shares
CY2016Q3	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	20000000	shares
CY2015Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	60600	shares
CY2016Q3	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	60600	shares
CY2015Q4	us-gaap	Preferred Stock Value PreferredStockValue	60	USD
CY2016Q3	us-gaap	Preferred Stock Value PreferredStockValue	60	USD
CY2015Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	789285	USD
CY2016Q3	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	946388	USD
	us-gaap	Proceeds From Debt Net Of Issuance Costs ProceedsFromDebtNetOfIssuanceCosts	0	USD
	us-gaap	Proceeds From Debt Net Of Issuance Costs ProceedsFromDebtNetOfIssuanceCosts	7805086	USD
	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	61215398	USD
	us-gaap	Proceeds From Long Term Lines Of Credit ProceedsFromLongTermLinesOfCredit	792251	USD
	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	818251	USD
	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	366966	USD
	us-gaap	Proceeds From Warrant Exercises ProceedsFromWarrantExercises	1389427	USD
	us-gaap	Proceeds From Warrant Exercises ProceedsFromWarrantExercises	0	USD
CY2015Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	3545361	USD
CY2016Q3	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	6194279	USD
CY2015Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	2690579	USD
CY2016Q3	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	4654876	USD
	us-gaap	Repayments Of Long Term Debt RepaymentsOfLongTermDebt	0	USD
	us-gaap	Repayments Of Long Term Debt RepaymentsOfLongTermDebt	8896166	USD
CY2015Q3	us-gaap	Research And Development Expense Excluding Acquired In Process Cost ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost	2546533	USD
	us-gaap	Research And Development Expense Excluding Acquired In Process Cost ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost	7428349	USD
	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	2293857	USD
	us-gaap	Proceeds From Issuance Or Sale Of Equity ProceedsFromIssuanceOrSaleOfEquity	2400000	USD
	us-gaap	Proceeds From Long Term Lines Of Credit ProceedsFromLongTermLinesOfCredit	0	USD
CY2016Q3	us-gaap	Research And Development Expense Excluding Acquired In Process Cost ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost	3937398	USD
	us-gaap	Research And Development Expense Excluding Acquired In Process Cost ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost	11221876	USD
CY2015Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-108887243	USD
CY2016Q3	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-139561491	USD
CY2015Q3	us-gaap	Royalty Revenue RoyaltyRevenue	51301	USD
	us-gaap	Royalty Revenue RoyaltyRevenue	222931	USD
CY2016Q3	us-gaap	Royalty Revenue RoyaltyRevenue	47236	USD
	us-gaap	Royalty Revenue RoyaltyRevenue	207869	USD
CY2015Q3	us-gaap	Sales Revenue Net SalesRevenueNet	57327	USD
	us-gaap	Sales Revenue Net SalesRevenueNet	233643	USD
CY2016Q3	us-gaap	Sales Revenue Net SalesRevenueNet	89114	USD
	us-gaap	Sales Revenue Net SalesRevenueNet	313000	USD
CY2015Q3	us-gaap	Selling And Marketing Expense SellingAndMarketingExpense	1798263	USD
	us-gaap	Selling And Marketing Expense SellingAndMarketingExpense	4508766	USD
CY2016Q3	us-gaap	Selling And Marketing Expense SellingAndMarketingExpense	2940862	USD
	us-gaap	Selling And Marketing Expense SellingAndMarketingExpense	9127450	USD
	us-gaap	Share Based Compensation ShareBasedCompensation	2758847	USD
	us-gaap	Share Based Compensation ShareBasedCompensation	5942392	USD
CY2015Q4	us-gaap	Short Term Investments ShortTermInvestments	0	USD
CY2016Q3	us-gaap	Short Term Investments ShortTermInvestments	24376904	USD
CY2015Q4	us-gaap	Stockholders Equity StockholdersEquity	48701289	USD
CY2016Q3	us-gaap	Stockholders Equity StockholdersEquity	26774399	USD
CY2015Q3	us-gaap	Unrealized Gain Loss On Derivatives UnrealizedGainLossOnDerivatives	4017212	USD
	us-gaap	Unrealized Gain Loss On Derivatives UnrealizedGainLossOnDerivatives	-1105270	USD
CY2016Q3	us-gaap	Unrealized Gain Loss On Derivatives UnrealizedGainLossOnDerivatives	88208	USD
	us-gaap	Unrealized Gain Loss On Derivatives UnrealizedGainLossOnDerivatives	674834	USD
CY2015Q3	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	29128235	shares
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	25204307	shares
CY2016Q3	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	30339774	shares
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	30136572	shares
CY2015Q3	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	28560211	shares
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	25014966	shares
CY2016Q3	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	30339774	shares
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	30018841	shares
	us-gaap	Use Of Estimates UseOfEstimates	<div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Use of Estimates</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div><div style="line-height:120%;text-indent:45px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates.</font></div></div>

Files In Submission

Name	View Source	Status
0001628280-16-021098-index-headers.html	Edgar Link	pending
0001628280-16-021098-index.html	Edgar Link	pending
0001628280-16-021098.txt	Edgar Link	pending
0001628280-16-021098-xbrl.zip	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
Financial_Report.xlsx	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending
trov-093016exhibit311.htm	Edgar Link	pending
trov-093016exhibit321.htm	Edgar Link	pending
trov-093016x10q.htm	Edgar Link	pending
trov-20160930.xml	Edgar Link	completed
trov-20160930.xsd	Edgar Link	pending
trov-20160930_cal.xml	Edgar Link	unprocessable
trov-20160930_def.xml	Edgar Link	unprocessable
trov-20160930_lab.xml	Edgar Link	unprocessable
trov-20160930_pre.xml	Edgar Link	unprocessable

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$CRDF
Cardiff Oncology, Inc. Stock $crdf

2016 Q3 Form 10-Q Financial Statement

#000162828016021098 Filed on November 09, 2016

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$CRDF Cardiff Oncology, Inc. Stock $crdf

2016 Q3 Form 10-Q Financial Statement

#000162828016021098 Filed on November 09, 2016

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$CRDF
Cardiff Oncology, Inc. Stock $crdf